Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01719926
Other study ID # NL40487.041.12
Secondary ID
Status Completed
Phase Phase 1
First received October 30, 2012
Last updated August 15, 2017
Start date September 2012
Est. completion date August 2017

Study information

Verified date August 2017
Source UMC Utrecht
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are recruited to the stroma of both the primary tumor and metastasis. Recent preclinical research has shown that in response to platinum-based chemotherapy, MSCs secrete two specific platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the COX-1 pathway. COX inhibitors, including indomethacin. This phase 1 study explores the safety of combining indomethacin with platinum containing chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects with a histological proven malignancy receiving cisplatin combined with gemcitabine or 5FU/capecitabine. (cisplatin dose range 60-80 mg/m2) (Arm I) or CAPOX (oxaliplatin, capecitabine) (Arm II) in a 21 day cycle.

- Age = 18 years

- Platinum-based chemotherapy naïve for at least 6 months.

- Subjects with at least one evaluable lesion.

- WHO Performance Status of 0 or 1.

- Female participants should be of non-child bearing potential either physiologic or by using adequate contraception, have a negative serum pregnancy test, and refrain from breast feeding.

- Written informed consent.

Exclusion Criteria:

- Known or suspected allergy or hypersensitivity to indomethacin or any agent given in association with this trial, in particular subjects who have a history of severe hypersensitivity reactions to anti-emetics (5-HT3 antagonists, metoclopramide or corticosteroids) and acetylsalicylic acid or other prostaglandin synthetase inhibitors.

- Symptomatic brain or meningeal tumors

- Subjects with seizure disorder requiring medication (such as corticosteroids or anti-epileptics).

- Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:

- Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen

- Unstable angina pectoris

- Symptomatic congestive heart failure NYHA class = 3 (see appendix 13.6)

- Myocardial infarction = 6 months prior to randomization

- Serious uncontrolled cardiac arrhythmia

- Active peptic ulcer disease, gastritis, inflammatory bowel disease.

- History of active gastrointestinal bleeding

- History of cerebrovascular disease

- Bleeding diathesis

- Chronic renal disease defined as GFR (MDRD) <60 ml/min

- Absolute Neutrophil Count (ANC) < 1.5 x 109/L (< 1500/mm3)

- Platelets (PLT) < 100 x 109/L (< 100,000/mm3)

- Hemoglobin (Hgb) < 6.0 mmol/l (patients may be transfused to achieve adequate Hb)

- Partial thromboplastin time (PTT) > 1,5 x ULN

- Serum bilirubin > 1.5 ULN

- Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) > 3.0 x ULN (> 5 x ULN if liver metastases present)

- Patients who are unable or unwilling to comply with the protocol

- Chronic treatment with a corticosteroid agent (nebulized corticosteroids are allowed)

- Patients who received radiation therapy within 4 weeks of the start of the study

- Patients who received an experimental agent less than 4 weeks before start of the study.

- Patients who used Omega-3/omega-6 containing products, including fish oil products less than 2 weeks before start of the study.

- Chronic use of NSAID's and/or acetylsalicylic acid and/or other prostaglandin synthetase inhibitors.

- Use of anticoagulant therapy

Study Design


Intervention

Drug:
Indomethacin
3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.

Locations

Country Name City State
Netherlands Meander Medisch Centrum Amersfoort Utrecht
Netherlands the Netherlands Cancer Institute Amsterdam
Netherlands UMC Utrecht Utrecht
Switzerland Oncology Institute of Southern Switzerland Bellinzona

Sponsors (1)

Lead Sponsor Collaborator
UMC Utrecht

Countries where clinical trial is conducted

Netherlands,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of dose limiting toxicities at each dosage cohort From first dose of indomethacin until 28 days after last dose of indomethacin
Secondary Pharmacodynamics Serum levels of mesenchymal stem cells and platinum induced fatty acids at T = pre-chemotherapy, one, two and four hours expressed in pmol/L. During first 2 cycles of 3 weeks each
Secondary Efficacy Efficacy will be assessed according RECIST 1.1 criteria. Progression free survival is defined as time from baseline CT scan to progressive disease according RECIST 1.1 criteria. From baseline to date of progressive disease according RECIST 1.1, approximately 9 to 18 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A
Completed NCT00947206 - Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans N/A